Summary
Generic biologicals Patent expiration Kenneth Cleaver, Ph.D.
Analysis
This is an accurate assessment because the development of generic biotech products is much more difficult than it is for traditional pharmaceuticals. Once a company has approval for a biotech product, the revenue stream will continue for a much longer period than the patent expiration date. There are very few generic companies that have either the technical or financial resources to develop generic biologicals.Kenneth Cleaver, Ph.D.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
